Ability of a new oral nicotine substitute to reduce smoking urge in moderate smokers

Addict Behav. 2006 Mar;31(3):537-43. doi: 10.1016/j.addbeh.2005.05.017. Epub 2005 Jun 17.


The aim of this study was to assess the effectiveness of a new nicotine lozenge ( Nicopass 1.5 mg) in reducing smoking urge after an overnight abstinence. Twenty-four moderate smokers participated in a randomized, double-blind, placebo-controlled, 2-period crossover trial. The results showed that 1.5 mg-nicotine lozenge is superior to placebo in reducing smoking urge (p = 0.0001). In addition, nicotine lozenge, but not placebo, significantly improved vigilance and psychomotor performances (p < 0.05) and displayed a cardiac chronotropic effect. Thus, the 1.5-mg nicotine lozenge appears as an effective aid to alleviate acute tobacco withdrawal symptoms in moderate smokers.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Administration, Oral
  • Adult
  • Cross-Over Studies
  • Double-Blind Method
  • Female
  • Heart Rate / drug effects
  • Humans
  • Male
  • Nicotine / therapeutic use*
  • Nicotinic Agonists / therapeutic use*
  • Psychomotor Performance / drug effects
  • Smoking / adverse effects
  • Smoking / drug therapy*
  • Smoking / psychology
  • Smoking Cessation / methods*
  • Substance Withdrawal Syndrome / drug therapy*
  • Substance Withdrawal Syndrome / etiology


  • Nicotinic Agonists
  • Nicotine